These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12018454)

  • 1. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei D; Groshen S; Lenz HJ
    Int J Colorectal Dis; 2002 Jan; 17(1):46-9. PubMed ID: 12018454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.
    Pullarkat ST; Stoehlmacher J; Ghaderi V; Xiong YP; Ingles SA; Sherrod A; Warren R; Tsao-Wei D; Groshen S; Lenz HJ
    Pharmacogenomics J; 2001; 1(1):65-70. PubMed ID: 11913730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
    Ribelles N; López-Siles J; Sánchez A; González E; Sánchez MJ; Carabantes F; Sánchez-Rovira P; Márquez A; Dueñas R; Sevilla I; Alba E
    Curr Drug Metab; 2008 May; 9(4):336-43. PubMed ID: 18473752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
    Baroudi O; Baroudi T; Omrane I; Moussa A; Mezlini A; Ayari H; Guermazi S; Bahloul A; Bouzaienne H; Uhrhammer N; Bignon YJ; El-Gaaied AB; Bougatef K
    Med Oncol; 2014 Feb; 31(2):825. PubMed ID: 24415354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
    Lindebjerg J; Nielsen JN; Hoeffding LD; Jakobsen A
    APMIS; 2005 Sep; 113(9):600-2. PubMed ID: 16218935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
    Uchida K; Hayashi K; Kawakami K; Schneider S; Yochim JM; Kuramochi H; Takasaki K; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2004 Jan; 10(2):433-9. PubMed ID: 14760062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase pharmacogenetics in colorectal cancer.
    Marsh S; McLeod HL
    Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
    Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
    Liu XF; Zhang H; Sun JQ; Yin C; Liu TF; Yang H; Chen LH
    Tumour Biol; 2014 Dec; 35(12):12409-14. PubMed ID: 25185651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
    Garcia AA; Blessing JA; Darcy KM; Lenz HJ; Zhang W; Hannigan E; Moore DH
    Gynecol Oncol; 2007 Mar; 104(3):572-9. PubMed ID: 17049588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    Iacopetta B; Grieu F; Joseph D; Elsaleh H
    Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in the treatment of colorectal cancer.
    Kelly C; Cassidy J
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):803-10. PubMed ID: 17555390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.